Skip to main content
SpringerLink
Log in

Reply to the Letter by S. Sorscher Regarding “Implications of BRAF Mutations in dMMR Colorectal Cancers”

  • Letter to the Editor
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

The Original Article was published on 10 August 2017

Abstract

ᅟ

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Overman MJ, Lonardi S, Leone F, McDermott RS, Morse MA, Wong KYM, et al. Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: update from CheckMate 142. J Clin Oncol. 2017 [cited 2017 Jan 24];35. Available from: http://meetinglibrary.asco.org/content/176629-195

  2. Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014;20:5322–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, Huynh TG, Mino-Kenudson M. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol. 2016;29:1104–12.

    Article  CAS  PubMed  Google Scholar 

  4. Kluger HM, Zito CR, Turcu G, Baine M, Zhang H, Adeniran A, et al. PD-L1 studies across tumor types, its differential expression and predictive value in patients treated with immune checkpoint inhibitors. Clin. Cancer Res. 2017;clincanres.3146.2016.

  5. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. Programmed death-1 blockade in mismatch repair deficient colorectal cancer. J Clin Oncol. 2016;34:suppl; abstr 103.

Download references

Author information

Authors and Affiliations

  1. Department of medical oncology, Hôpital Saint-Antoine, AP-HP, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France

    R. Cohen MD & T. André MD

Authors
  1. R. Cohen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. André MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. André MD.

Additional information

This reply refers to the comment available at https://doi.org/10.1007/s11864-017-0493-x

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cohen, R., André, T. Reply to the Letter by S. Sorscher Regarding “Implications of BRAF Mutations in dMMR Colorectal Cancers”. Curr. Treat. Options in Oncol. 18, 63 (2017). https://doi.org/10.1007/s11864-017-0505-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-017-0505-x

Keywords

Search

Navigation